

## Tilvestamab

Cat. No.:	HY-P99161
CAS No.:	2226775-26-2
Target:	TAM Receptor
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas <sup>[1]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	AXL <sup>[1]</sup> .									
<b>In Vitro</b>	<p>Tilvestamab (250 μM; 1 h) inhibits AXL phosphorylation in 786-0 cells<sup>[1]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>786-0-Luc cells (Gas6- induced; Gas6 is a well characterized AXL ligand)</td> </tr> <tr> <td>Concentration:</td> <td>250 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>1 h (pre-treat)</td> </tr> <tr> <td>Result:</td> <td>Drastically inhibited Gas6- induced AXL phosphorylation and decreased the level of pAKT.</td> </tr> </table>		Cell Line:	786-0-Luc cells (Gas6- induced; Gas6 is a well characterized AXL ligand)	Concentration:	250 μM	Incubation Time:	1 h (pre-treat)	Result:	Drastically inhibited Gas6- induced AXL phosphorylation and decreased the level of pAKT.
Cell Line:	786-0-Luc cells (Gas6- induced; Gas6 is a well characterized AXL ligand)									
Concentration:	250 μM									
Incubation Time:	1 h (pre-treat)									
Result:	Drastically inhibited Gas6- induced AXL phosphorylation and decreased the level of pAKT.									
<b>In Vivo</b>	<p>Tilvestamab (30 mg/kg; i.p.; twice a week) suppresses tumor growth by inhibiting AXL in orthotopic RCC model<sup>[1]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female BALB/c athymic nude mice (8-week-old; orthotopic RCC model)<sup>[1]</sup>.</td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; twice a week</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited RCC growth down to about 1/3 of the volume.</td> </tr> </table>		Animal Model:	Female BALB/c athymic nude mice (8-week-old; orthotopic RCC model) <sup>[1]</sup> .	Dosage:	30 mg/kg	Administration:	Intraperitoneal injection; twice a week	Result:	Significantly inhibited RCC growth down to about 1/3 of the volume.
Animal Model:	Female BALB/c athymic nude mice (8-week-old; orthotopic RCC model) <sup>[1]</sup> .									
Dosage:	30 mg/kg									
Administration:	Intraperitoneal injection; twice a week									
Result:	Significantly inhibited RCC growth down to about 1/3 of the volume.									

### REFERENCES

[1]. Chen TJ, et al. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model. *Physiol Rep*.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA